Key Insights

Highlights

Success Rate

97% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

2.6%

1 terminated out of 38 trials

Success Rate

97.3%

+10.8% vs benchmark

Late-Stage Pipeline

39%

15 trials in Phase 3/4

Results Transparency

14%

5 of 36 completed with results

Key Signals

5 with results97% success

Data Visualizations

Phase Distribution

26Total
P 1 (8)
P 2 (3)
P 3 (11)
P 4 (4)

Trial Status

Completed36
Withdrawn1
Terminated1

Trial Success Rate

97.3%

Benchmark: 86.5%

Based on 36 completed trials

Clinical Trials (38)

Showing 20 of 20 trials
NCT02616562Phase 2CompletedPrimary

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency

NCT01562834Phase 4CompletedPrimary

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

NCT01514500Phase 1CompletedPrimary

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

NCT01706783Phase 1CompletedPrimary

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

NCT01973244Phase 1CompletedPrimary

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

NCT02229851Phase 3CompletedPrimary

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

NCT03075644Phase 3CompletedPrimary

A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency

NCT02382939Phase 3Completed

A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency

NCT03186495Phase 1CompletedPrimary

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function

NCT01580605CompletedPrimary

French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

NCT03212131Phase 1CompletedPrimary

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

NCT00960128CompletedPrimary

Observational Prospective Study on Patients Treated With Norditropin®

NCT01009905CompletedPrimary

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

NCT01502124Phase 3CompletedPrimary

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT00567385Phase 4CompletedPrimary

Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

NCT00184743Phase 3CompletedPrimary

Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

NCT00519558Phase 3CompletedPrimary

Growth Hormone Deficiency in Adults (GHDA)

NCT00931476Phase 1CompletedPrimary

A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin

NCT01563926Phase 3CompletedPrimary

Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency

NCT01698944Phase 4TerminatedPrimary

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

Scroll to load more

Research Network

Activity Timeline